EUVIMEDEUVIMED entdecken
Crossref

ERAP1-dependent extreme antigen processing efficacy can govern MHC class I expression hierarchy

Jacqueline Leib iD, Emmanuelle Waeckel-Énée, Sylvie Fabrega, Nadia Keelan, Alice Senni iD, François-Xavier Mauvais, Rebecca Deprez-Poulain iD, Barbara Bertocci iD, Peter van Endert iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Jacqueline Leib und 8 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, Paris, France. Hauptthemen laut MEDLINE: Minor Histocompatibility Antigens, Aminopeptidases, Antigen Presentation, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Agence Nationale de Recherche, Fondation pour la Recherche Médicale, European Training Network CAPSTONE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide presentation by major histocompatibility complex (MHC) class I molecules enables CD8+ T lymphocytes to monitor the intracellular proteome of tissue cells. CD8+ T cell priming and acquisition of effector functions is affected by cognate peptide-MHC-I complex density on the cell surface, which partly depends on the efficacy of intracellular proteolytic peptide generation. Peptide generation frequently requires final trimming by the human aminopeptidases ERAP1, ERAP2, and IRAP. All display genetic polymorphism associated with the risk of multiple autoimmune diseases but also some cancers. This finding has prompted interest in the development of small molecule inhibitors to enhance antitumor or conversely attenuate autoreactive T cell responses. However, efficient assays for assessment of inhibitor effects are wanting. We describe the development of an assay for quantitative assessment by flow cytometry of selective inhibitor effects on peptide trimming both in the endogenous MHC-I processing pathway and in cross-presentation. We use the assay to identify a selective ERAP2 inhibitor and show that inhibitor effects can be read out not only through assessing a specific peptide-MHC complexes but also by measuring cell surface levels of bulk MHC-I molecules. Next to its practical interest as tool for inhibitor testing, our assay highlights how ERAP1-dependent immunodominance of a single epitope processed with exceptional efficacy can have a massive effect on the immunopeptidomic identity of cells presented to CD8+ T cells. We propose that ERAP effects on the presentation of such rare and exceptionally immunodominant epitopes may underlie the epistatic genetic associations of ERAP polymorphism with HLA class I-linked autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Minor Histocompatibility AntigensAminopeptidasesAntigen PresentationHistocompatibility Antigens Class ICD8-Positive T-LymphocytesHumansPeptidesCross-Priming

Stichwörter der Autor:innen

MHC class Iantigen presentationantigen processingendoplasmic reticulum aminopeptidaseovalbuminpeptide trimming

Substanzen

Minor Histocompatibility AntigensAminopeptidasesERAP1 protein, humanHistocompatibility Antigens Class IERAP2 protein, humanPeptides

Autor:innen und Institutionen

  • Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, Paris, France.
  • Viral Vector for Gene Transfer Core Facility, Université de Paris Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR3633, Paris, France.
  • Service de Physiologie-Explorations Fonctionnelles Pédiatriques, AP-HP, Hôpital Universitaire Robert Debré, Paris, France.
  • Univ. Lille, INSERM, Institut Pasteur de Lille, U1177 - EGID Drugs and Molecules for Living Systems, Lille, France.
  • Service Immunologie Biologique, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Paris, France.

ORCID-Profile: Jacqueline Leib, Alice Senni, Rebecca Deprez-Poulain, Barbara Bertocci, Peter van Endert

Förderung

  • Agence Nationale de Recherche
  • Fondation pour la Recherche Médicale
  • European Training Network CAPSTONE

Zitieren

APA

Leib, J., Waeckel-Énée, E., Fabrega, S., Keelan, N., Senni, A., Mauvais, F. X., Deprez-Poulain, R., Bertocci, B., & van Endert, P. (2025). ERAP1-dependent extreme antigen processing efficacy can govern MHC class I expression hierarchy. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf013

Vancouver

Leib J, Waeckel-Énée E, Fabrega S, Keelan N, Senni A, Mauvais FX, et al. ERAP1-dependent extreme antigen processing efficacy can govern MHC class I expression hierarchy. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf013

BibTeX
@article{Leib2025,
  author = {Leib, Jacqueline and Waeckel-Énée, Emmanuelle and Fabrega, Sylvie and Keelan, Nadia and Senni, Alice and Mauvais, François-Xavier and Deprez-Poulain, Rebecca and Bertocci, Barbara and van Endert, Peter},
  title = {ERAP1-dependent extreme antigen processing efficacy can govern MHC class I expression hierarchy},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf013}
}
Kostenlos starten →